Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | MPO | P05164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28621819 | 0.70 | WNT1 (0.37) | LMNACCNCCDK8 | |
| SCHEMBL3573733 | 0.70 | CNR1 (0.58) | — | |
| SCHEMBL3568121 | 0.69 | HTR6 (0.38) | ALDH1A1LMNA | |
| SCHEMBL15799303 | 0.68 | BTK (0.49) | — | |
| SCHEMBL15799260 | 0.68 | BTK (0.48) | — | |
| SCHEMBL29479422 | 0.67 | HRH3 (0.58) | ALKBH5FTOGPR84SLC6A4MPO | |
| SCHEMBL26508390 | 0.65 | MPO (0.61) | ALKBH5FTOGPR84SLC6A4MPO | |
| SCHEMBL11329325 | 0.64 | ALDH1A1 (0.62) | ALDH1A1HTTKDM4EMAPTTDP1 | |
| SCHEMBL6421446 | 0.64 | KDM4E (0.44) | ALDH1A1HTTKDM4EMAPTTDP1 | |
| SCHEMBL8177052 | 0.63 | TBK1 (0.45) | ALDH1A1HTTKDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| CN-100522161-C | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2009-08-05 | — | — | CN | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| CN-1929836-A | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | ALKBH5 3459/4885FTO 3166/4885GPR84 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.